Vikas Satyananda1, Ron Shapiro. 1. Multiorgan Transplant Surgery, Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Calcineurin inhibitors (CNIs) play a major role in long-term renal allograft dysfunction because of their nephrotoxic side-effects. Belatacept, a selective costimulation blockade agent, is the first biological agent approved for maintenance immunosuppression in renal transplantation. RECENT FINDINGS: Studies have shown better preservation of glomerular filtration rate and improved metabolic end points with belatacept when compared with CNIs. More recent studies have shown that belatacept can be an effective first-line immunosuppressive agent with complete avoidance of CNIs and corticosteroids. SUMMARY: Newer biological agents like belatacept may replace CNIs/corticosteroids in renal transplant recipients, with a benefit of better short-term and long-term renal function, better compliance, and ultimately a possible improvement in long-term renal allograft survival.
PURPOSE OF REVIEW: Calcineurin inhibitors (CNIs) play a major role in long-term renal allograft dysfunction because of their nephrotoxic side-effects. Belatacept, a selective costimulation blockade agent, is the first biological agent approved for maintenance immunosuppression in renal transplantation. RECENT FINDINGS: Studies have shown better preservation of glomerular filtration rate and improved metabolic end points with belatacept when compared with CNIs. More recent studies have shown that belatacept can be an effective first-line immunosuppressive agent with complete avoidance of CNIs and corticosteroids. SUMMARY: Newer biological agents like belatacept may replace CNIs/corticosteroids in renal transplant recipients, with a benefit of better short-term and long-term renal function, better compliance, and ultimately a possible improvement in long-term renal allograft survival.
Authors: J S Young; J Chen; M L Miller; V Vu; C Tian; J J Moon; M-L Alegre; R Sciammas; A S Chong Journal: Am J Transplant Date: 2016-04-04 Impact factor: 8.086
Authors: A Paliege; J Bamoulid; F Bachmann; O Staeck; F Halleck; D Khadzhynov; S Brakemeier; M Dürr; K Budde Journal: Urologe A Date: 2015-10 Impact factor: 0.639
Authors: Sangho Lim; Nancy C Kirkiles-Smith; Jordan S Pober; Alfred L M Bothwell; Je-Min Choi Journal: Biomaterials Date: 2018-08-21 Impact factor: 12.479
Authors: Pedro M Moraes-Vieira; Angela Castoldi; Pratik Aryal; Kerry Wellenstein; Odile D Peroni; Barbara B Kahn Journal: Diabetes Date: 2016-03-02 Impact factor: 9.461